Learn more about Peter Attia’s digital program
#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D.
“What we try to do is quite simple. We try to find drugs that will slow aging and extend mouse lifespan.” —Rich Miller
#272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more | David Sabatini, M.D., Ph.D. and Matt Kaeberlein, Ph.D.
“[Rapamycin] is the most robust and reproducible drug that we know about today for impacting not only longevity, but to the extent that we can measure various metrics of healthspan in complex animals, rapamycin also seems to positively impact pretty much every aspect of health span that we measure.” —Matt Kaeberlein
#207 – AMA #35: “Anti-Aging” Drugs — NAD+, metformin, & rapamycin
“It’s really hard to know, in my view, how important sirtuins are as longevity factors…If we accept that, then it’s difficult to know [the importance of] activation of sirtuins by NAD as a longevity mechanism.” —Matt Kaeberlein
#204 – Centenarians, metformin, and longevity | Nir Barzilai, M.D.
“If you prevent aging and age-related disease, you’re going to compress morbidity, too.” — Nir Barzilai
How long can we live?; suggested listening
Revisiting the podcast archive
Are continuous glucose monitors a waste of time for people without diabetes?
Some experts suggest CGMs are useless for nondiabetics. I disagree.
Does NMN improve metabolic health in humans?
Thoughts on the first efficacy trial recently published